Abbott Laboratories (ABT) Shares are Up 1.14%

Abbott Laboratories (ABT) : Traders are bullish on Abbott Laboratories (ABT) as it has outperformed the S&P 500 by a wide margin of 5.42% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.71%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.14% in the last 1 week, and is up 8.04% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Abbott Laboratories (NYSE:ABT): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $45.00 and $44.87 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $45.41. The buying momentum continued till the end and the stock did not give up its gains. It closed at $45.26, notching a gain of 1.00% for the day. The total traded volume was 6,555,269 . The stock had closed at $44.81 on the previous day.

The stock has recorded a 20-day Moving Average of 4.67% and the 50-Day Moving Average is 12.04%. Abbott Laboratories is up 19.93% in the last 3-month period. Year-to-Date the stock performance stands at 2.66%.

Abbott Laboratories (ABT) : The most positive equity analysts on Abbott Laboratories (ABT) expects the shares to touch $52, whereas, the least positive believes that the stock will trade at $45 in the short term. The company is covered by 11 Wall Street Brokerage Firms. The average price target for shares are $48.82 with an expected fluctuation of $1.78 from the mean.


Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.